A new study says a flood of fake or poor quality anti-malaria drugs throughout Africa and Asia over the last decade poses a major risk in the effort to combat the mosquito-borne disease. The report by the U.S. National Institutes of Health says an analysis of data collected from 21 sub-Saharan African nations discovered that 35 percent of anti-malarial drugs failed chemical testing because they were poorly manufactured, while another 20 percent were bogus. In a similar analysis of ...
No comments:
Post a Comment